Korea Spotlight: How OliX is spreading its siRNA beyond Korea’s borders

The launch of an mRNA subsidiary is the latest move by RNAi company OliX to build upon its trio of partnerships and bicoastal beachhead of U.S. offices to realize its global ambitions.

OliX Pharmaceuticals Inc., which develops nucleic acid-based therapeutics using RNA interference technology, decided to found its new unit, mCureX Therapeutics Inc., early this year to capitalize on the expertise of its director of oligonucleotide chemistry, Dong Won Shin. Shin specializes in modified nucleic acid technologies including co-transcriptional reagents for mRNA capping and mRNA with natural and chemically modified nucleosides...